Date: 2011-01-11
Type of information:
Compound: novel targets in the field of autoimmune disease
Company: Biofocus, a Galapagos Company (UK - Belgium) Ono Pharmaceutical (Japan)
Therapeutic area: Autoimmune diseases
Type agreement: R&D
Action mechanism:
Disease: Autoimmune diseases
Details: Ono Pharmaceutical and BioFocus have signed a collaboration agreement, focused on discovering novel targets in the field of autoimmune disease. Under the agreement, BioFocus will receive research funding and success payments based on the progress of the collaboration. BioFocus will utilize its unique SilenceSelect® target discovery platform to deliver validated targets for Ono’s immunology programs. Ono aims to find modulators for these targets and generate novel and innovative drug candidates.
Financial terms:
Latest news:
